S&P 500   4,130.37 (-0.36%)
DOW   32,786.65 (-0.05%)
QQQ   320.29 (-0.45%)
AAPL   164.78 (-0.34%)
MSFT   279.96 (-1.04%)
META   171.18 (+2.44%)
GOOGL   117.34 (-0.11%)
AMZN   138.98 (-1.29%)
TSLA   879.03 (+1.68%)
NVDA   174.54 (-8.08%)
NIO   20.29 (+0.35%)
BABA   90.72 (-1.99%)
AMD   99.57 (-2.68%)
MU   61.54 (-1.47%)
T   18.11 (-1.31%)
CGC   3.20 (+18.52%)
GE   75.68 (+1.78%)
F   15.91 (+3.99%)
DIS   109.25 (+2.46%)
AMC   24.83 (+11.95%)
PYPL   96.19 (+0.91%)
PFE   49.20 (-0.14%)
NFLX   235.09 (+3.66%)
S&P 500   4,130.37 (-0.36%)
DOW   32,786.65 (-0.05%)
QQQ   320.29 (-0.45%)
AAPL   164.78 (-0.34%)
MSFT   279.96 (-1.04%)
META   171.18 (+2.44%)
GOOGL   117.34 (-0.11%)
AMZN   138.98 (-1.29%)
TSLA   879.03 (+1.68%)
NVDA   174.54 (-8.08%)
NIO   20.29 (+0.35%)
BABA   90.72 (-1.99%)
AMD   99.57 (-2.68%)
MU   61.54 (-1.47%)
T   18.11 (-1.31%)
CGC   3.20 (+18.52%)
GE   75.68 (+1.78%)
F   15.91 (+3.99%)
DIS   109.25 (+2.46%)
AMC   24.83 (+11.95%)
PYPL   96.19 (+0.91%)
PFE   49.20 (-0.14%)
NFLX   235.09 (+3.66%)
S&P 500   4,130.37 (-0.36%)
DOW   32,786.65 (-0.05%)
QQQ   320.29 (-0.45%)
AAPL   164.78 (-0.34%)
MSFT   279.96 (-1.04%)
META   171.18 (+2.44%)
GOOGL   117.34 (-0.11%)
AMZN   138.98 (-1.29%)
TSLA   879.03 (+1.68%)
NVDA   174.54 (-8.08%)
NIO   20.29 (+0.35%)
BABA   90.72 (-1.99%)
AMD   99.57 (-2.68%)
MU   61.54 (-1.47%)
T   18.11 (-1.31%)
CGC   3.20 (+18.52%)
GE   75.68 (+1.78%)
F   15.91 (+3.99%)
DIS   109.25 (+2.46%)
AMC   24.83 (+11.95%)
PYPL   96.19 (+0.91%)
PFE   49.20 (-0.14%)
NFLX   235.09 (+3.66%)
S&P 500   4,130.37 (-0.36%)
DOW   32,786.65 (-0.05%)
QQQ   320.29 (-0.45%)
AAPL   164.78 (-0.34%)
MSFT   279.96 (-1.04%)
META   171.18 (+2.44%)
GOOGL   117.34 (-0.11%)
AMZN   138.98 (-1.29%)
TSLA   879.03 (+1.68%)
NVDA   174.54 (-8.08%)
NIO   20.29 (+0.35%)
BABA   90.72 (-1.99%)
AMD   99.57 (-2.68%)
MU   61.54 (-1.47%)
T   18.11 (-1.31%)
CGC   3.20 (+18.52%)
GE   75.68 (+1.78%)
F   15.91 (+3.99%)
DIS   109.25 (+2.46%)
AMC   24.83 (+11.95%)
PYPL   96.19 (+0.91%)
PFE   49.20 (-0.14%)
NFLX   235.09 (+3.66%)

Novartis - NVS Stock Forecast, Price & News

$85.87
+0.30 (+0.35%)
(As of 08/8/2022 02:39 PM ET)
Add
Compare
Today's Range
$85.65
$86.35
50-Day Range
$80.52
$91.46
52-Week Range
$79.09
$95.17
Volume
58,204 shs
Average Volume
2.45 million shs
Market Capitalization
$190.00 billion
P/E Ratio
8.39
Dividend Yield
2.52%
Price Target
$87.33

Novartis MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1.8% Upside
$87.33 Price Target
Short Interest
Healthy
0.27% of Shares Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.34mentions of Novartis in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
10.23%
From $6.06 to $6.68 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

Medical Sector

980th out of 1,293 stocks

Pharmaceutical Preparations Industry

469th out of 619 stocks

NVS stock logo

About Novartis (NYSE:NVS) Stock

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Analyst Ratings Changes

Several brokerages have commented on NVS. Wolfe Research cut shares of Novartis from an "outperform" rating to a "market perform" rating in a research report on Monday, May 9th. Barclays boosted their price target on Novartis from CHF 80 to CHF 85 in a research report on Thursday, April 14th. raised Novartis from a "hold" rating to a "buy" rating in a research report on Thursday, April 14th. Morgan Stanley boosted their target price on Novartis from CHF 90 to CHF 94 in a report on Friday, May 6th. Finally, JPMorgan Chase & Co. raised their price target on Novartis from CHF 80 to CHF 81 and gave the company an "underweight" rating in a report on Wednesday, July 20th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $87.33.

Novartis Stock Up 0.9 %

NVS Stock traded up $0.76 during trading on Monday, reaching $86.33. 25,477 shares of the company traded hands, compared to its average volume of 2,449,032. Novartis has a 12 month low of $79.09 and a 12 month high of $95.17. The business has a 50 day simple moving average of $85.04 and a 200 day simple moving average of $86.59. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.13 and a current ratio of 1.38. The company has a market capitalization of $191.01 billion, a price-to-earnings ratio of 8.36, a price-to-earnings-growth ratio of 2.42 and a beta of 0.51.

Novartis (NYSE:NVS - Get Rating) last posted its quarterly earnings data on Monday, July 18th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.52 by $0.04. Novartis had a net margin of 44.31% and a return on equity of 21.88%. The business had revenue of $12.78 billion during the quarter, compared to analyst estimates of $12.78 billion. During the same quarter last year, the firm posted $1.64 earnings per share. The business's revenue for the quarter was down 1.4% compared to the same quarter last year. On average, equities research analysts anticipate that Novartis will post 6.06 earnings per share for the current fiscal year.

Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

NVS Stock News Headlines

Analysts Set Novartis AG (NYSE:NVS) Price Target at $87.33
A $226B Copper Spending Jackpot
On November 15, 2021, President Biden signed the biggest infrastructure spending bill of all time. A staggering $226 BILLION is earmarked for projects requiring huge amounts of copper. Turns out, copper is a desperately needed mineral to power the green revolution of clean, renewable energy.
A $226B Copper Spending Jackpot
On November 15, 2021, President Biden signed the biggest infrastructure spending bill of all time. A staggering $226 BILLION is earmarked for projects requiring huge amounts of copper. Turns out, copper is a desperately needed mineral to power the green revolution of clean, renewable energy.
What This FDA Delay Means for Novartis
Analysts Set Novartis AG (NYSE:NVS) PT at $88.13
Analysts Set Novartis AG (NYSE:NVS) PT at $88.13
See More Headlines
Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

NVS Company Calendar

Last Earnings
7/18/2022
Today
8/08/2022
Next Earnings (Estimated)
10/25/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
104,323
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$87.33
High Stock Price Forecast
$105.00
Low Stock Price Forecast
$75.00
Forecasted Upside/Downside
+1.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
12 Analysts

Profitability

Net Income
$24.02 billion
Pretax Margin
47.99%

Debt

Sales & Book Value

Annual Sales
$52.88 billion
Cash Flow
$9.05 per share
Book Value
$30.32 per share

Miscellaneous

Outstanding Shares
2,212,600,000
Free Float
2,212,379,000
Market Cap
$190.00 billion
Optionable
Optionable
Beta
0.51

Social Links


Key Executives

  • Dr. Vasant Narasimhan (Age 46)
    Chief Exec. Officer
    Comp: $4.96M
  • Mr. Harry Kirsch (Age 57)
    Chief Financial Officer
    Comp: $2.76M
  • Dr. Klaus Moosmayer Ph.D. (Age 54)
    Chief Ethics, Risk & Compliance Officer
    Comp: $1.35M
  • Ms. Karen L. Hale (Age 54)
    Chief Legal Officer
    Comp: $2.02M
  • Dr. Robert Kowalski Pharm.D. (Age 54)
    Chief People & Organization Officer
    Comp: $1.16M
  • Mr. Steffen Lang Ph.D. (Age 55)
    Pres of Operations
    Comp: $2.29M
  • Ms. Marie-France Tschudin (Age 51)
    Pres of Innovative Medicines International & Chief Commercial Officer
    Comp: $2.51M
  • Mr. Richard Saynor (Age 55)
    Chief Exec. Officer of Sandoz
    Comp: $1.82M
  • Dr. James E. Bradner M.D. (Age 50)
    Pres of Novartis Institutes for Biomedical Research
    Comp: $3.07M
  • Paul Penepent
    Head of Group Financial Reporting and Accounting













NVS Stock - Frequently Asked Questions

Should I buy or sell Novartis stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.
View NVS analyst ratings
or view top-rated stocks.

What is Novartis' stock price forecast for 2022?

12 analysts have issued 12-month price objectives for Novartis' shares. Their NVS stock forecasts range from $75.00 to $105.00. On average, they predict the company's share price to reach $87.33 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price.
View analysts price targets for NVS
or view top-rated stocks among Wall Street analysts.

How has Novartis' stock price performed in 2022?

Novartis' stock was trading at $87.47 at the beginning of 2022. Since then, NVS stock has decreased by 1.7% and is now trading at $85.96.
View the best growth stocks for 2022 here
.

When is Novartis' next earnings date?

Novartis is scheduled to release its next quarterly earnings announcement on Tuesday, October 25th 2022.
View our NVS earnings forecast
.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) announced its quarterly earnings data on Monday, July, 18th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.52 by $0.04. The company earned $12.78 billion during the quarter, compared to analysts' expectations of $12.78 billion. Novartis had a net margin of 44.31% and a trailing twelve-month return on equity of 21.88%. The business's revenue for the quarter was down 1.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.64 EPS.

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis declared an annual dividend on Thursday, February 3rd. Shareholders of record on Wednesday, March 9th will be paid a dividend of $1.175 per share on Thursday, March 17th. This represents a yield of 1.36%. The ex-dividend date is Tuesday, March 8th.
Read our dividend analysis for NVS
.

Is Novartis a good dividend stock?

Novartis (NYSE:NVS) pays an annual dividend of $2.16 per share and currently has a dividend yield of 2.52%. The dividend payout ratio is 21.11%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVS will have a dividend payout ratio of 32.34% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVS.

What is Vas Narasimhan's approval rating as Novartis' CEO?

938 employees have rated Novartis Chief Executive Officer Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among the company's employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Who are Novartis' major shareholders?

Novartis' stock is owned by many different institutional and retail investors. Top institutional investors include Loomis Sayles & Co. L P (0.70%), Manning & Napier Group LLC (0.08%), Scharf Investments LLC (0.06%), Envestnet Asset Management Inc. (0.06%), Truist Financial Corp (0.04%) and Bristol John W & Co. Inc. NY (0.03%).

How do I buy shares of Novartis?

Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $85.96.

How much money does Novartis make?

Novartis (NYSE:NVS) has a market capitalization of $190.20 billion and generates $52.88 billion in revenue each year. The company earns $24.02 billion in net income (profit) each year or $10.23 on an earnings per share basis.

How many employees does Novartis have?

Novartis employs 104,323 workers across the globe.

Does Novartis have any subsidiaries?

The following companies are subsidiares of Novartis: 1 A Pharma GmbH, Abadia Retuerta S.A, Admune Therapeutics, Advanced Accelerator Applications, Advanced Accelerator Applications, Advanced Accelerator Applications International SA, Advanced Accelerator Applications S.A., Advanced Accelerator Applications S.r.l., Advanced Accelerator Applications USA Inc., Aeropharm GmbH, Alcon, Alcon – Couvreur NV, Amblyotech, Amblyotech Inc., Arctos Medical, Arctos Medical AG, Australia Pty Ltd, Beijing Novartis Pharma Co. Ltd., BioMedical Research Co. Ltd., CELLforCURE, Cadent Therapeutics, Cadent Therapeutics Cambridge, Cellerys, Cellerys AG, CellforCure, Chiron Corporation, Ciba-Geigy Japan Limited, Co. Ltd, CoStim Pharmaceuticals, CoStim Pharmaceuticals Inc., Coalesce Product Development Limited, Corthera, Development Co. Ltd., EBEWE Pharma Ges.m.b.H Nfg. KG, Encore Vision, Endocyte, Endocyte Inc., Eon Labs Inc., Farmanova Saglik Hizmetleri Ltd, Fougera Pharmaceuticals, Fougera Pharmaceuticals Inc, Gyroscope Therapeutics, HEXAL AG, Hexal, IDB Holland BV, Iberica S.L.U., Ilaçlari Sanayi ve Ticaret A.S, JSC Sandoz, Japat AG, Kedalion Therapeutics Inc., Lek Pharmaceuticals d.d., Lek S.A., Manufacturing Pte Ltd , Navigate BioPharma Services Inc, Neutec Pharma Limited, Novartis (Hellas) S.A.C.I., Novartis (Singapore) Pte Ltd, Novartis (Taiwan) Co. Ltd, Novartis (Thailand) Limited, Novartis Argentina S.A., Novartis Australia Pty Ltd, Novartis Austria GmbH, Novartis Biociências S.A., Novartis Biosciences Perú S.A., Novartis Bioventures AG, Novartis Business Services GmbH, Novartis Capital Corporation, Novartis Chile S.A., Novartis Corporation, Novartis Corporation Sdn. Bhd., Novartis Deutschland GmbH, Novartis Ecuador S.A., Novartis Farma S.p.A., Novartis Farma – Produtos Farmacêuticos S.A., Novartis Farmacéutica S.A, Novartis Farmacéutica S.A. de C.V., Novartis Finance Corporation, Novartis Finance S.A., Novartis Finance Services Ltd, Novartis Finland Oy Espoo, Novartis Gene Therapies, Novartis Gene Therapies EU Limited, Novartis Gene Therapies Inc., Novartis Grimsby Limited, Novartis Groupe France S.A., Novartis Healthcare A/S, Novartis Healthcare Philippines Inc., Novartis Healthcare Private Limited, Novartis Holding AG, Novartis Hungary Healthcare Limited Liability Company, Novartis India Limited, Novartis Inflammasome Research, Novartis Integrated Services Limited, Novartis International AG, Novartis International Pharmaceutical Investment AG, Novartis Investment Ltd, Novartis Investments S.à r.l., Novartis Ireland Limited, Novartis Israel Ltd, Novartis Korea Ltd., Novartis Middle East FZE, Novartis Netherlands B.V., Novartis Neva LLC, Novartis New Zealand Ltd, Novartis Norge AS, Novartis Ophthalmics AG, Novartis Optogenetics Research Inc., Novartis Overseas Investments AG, Novartis Pharma (Logistics) Inc., Novartis Pharma (Pakistan) Limited, Novartis Pharma AG, Novartis Pharma B.V. , Novartis Pharma GmbH, Novartis Pharma GmbH, Novartis Pharma K.K., Novartis Pharma LLC, Novartis Pharma Maroc SA, Novartis Pharma NV, Novartis Pharma Produktions GmbH, Novartis Pharma S.A.E., Novartis Pharma S.A.S., Novartis Pharma Schweiz AG, Novartis Pharma Schweizerhalle AG, Novartis Pharma Services AG, Novartis Pharma Services Romania S.R.L., Novartis Pharma Stein AG, Novartis Pharmaceuticals Canada Inc., Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Limited, Novartis Pharmaceuticals UK Limited, Novartis Poland Sp. z o.o., Novartis Portugal S.G.P.S. Lda., Novartis Ringaskiddy Limited, Novartis Saglik Gida ve Tarim Ürünleri Sanayi ve Ticaret A.S, Novartis Saudi Ltd., Novartis Securities Investment Ltd, Novartis Services Inc., Novartis Slovakia s.r.o., Novartis South Africa (Pty) Ltd, Novartis Sverige AB, Novartis UK Limited, Novartis US Foundation, Novartis Vaccines and Diagnostics Inc, Novartis Vietnam Company Limited, Novartis de Colombia S.A., Novartis de Venezuela S.A., Novartis s.r.o., Oriel Therapeutics Inc., PT. Novartis Indonesia, Protez Pharmaceuticals, Pte Ltd, Research Inc, Salutas Pharma GmbH, Sandoz A/S, Sandoz AG, Sandoz B.V., Sandoz Canada Inc., Sandoz Egypt Pharma S.A.E., Sandoz Farmacéutica S.A., Sandoz Farmacêutica Lda., Sandoz GmbH, Sandoz Hungary Limited Liability Company, Sandoz Ilaç Sanayi ve Ticaret A.S., Sandoz Inc, Sandoz Industrial Products S.A, Sandoz International GmbH, Sandoz K.K., Sandoz Limited, Sandoz Manufacturing Inc., Sandoz NV, Sandoz Pharma K.K, Sandoz Pharmaceuticals AG, Sandoz Pharmaceuticals d.d., Sandoz Philippines Corporation, Sandoz Polska Sp. z o.o. , Sandoz Private Limited, Sandoz Pty Ltd, Sandoz S.A. de C.V, Sandoz S.A.S., Sandoz S.R.L., Sandoz S.p.A., Sandoz South Africa (Pty) Ltd, Sandoz Ukraine LLC, Sandoz d.o.o. farmaceutska industrija, Sandoz do Brasil Indústria Farmacêutica Ltda, Sandoz s.r.o., Selexys Pharmaceuticals Corporation, Shanghai Novartis Trading Ltd., Société par actions SANDOZ, Spinifex Pharmaceuticals, The Medicines Company, The Medicines Company, Triangle International Reinsurance Limited, Trinity River Insurance Co Ltd, Vedere Bio, Vedere Bio ll, Xiidra, Ziarco, and Ziarco Group Limited.
Read More

When was Novartis founded?

Novartis was founded in 1996.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The official website for the company is www.novartis.com. The company can be reached via phone at (161) 324-1111, via email at investor.relations@novartis.com, or via fax at 41-61-324-7826.

This page (NYSE:NVS) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.